MLL polyclonal antibody (A01)

Catalog # H00004297-A01

Size

Price

Stock

Quantity

Size:50 uL
Price: USD $ 243.00
Stock:
order now, ship in 3 months
abnova-minus
abnova-plus

* The price is valid only in USA. Please select country.

Contact Info
  • +1-909-264-1399
    +1-909-992-0619
    Toll Free : +1-877-853-6098
  • +1-909-992-3401
Images
QC Test

Western Blot detection against Immunogen (38.21 KDa) .

  • Specification

    Product Description

    Mouse polyclonal antibody raised against a partial recombinant MLL.

    Immunogen

    MLL (NP_005924, 3561 a.a. ~ 3670 a.a) partial recombinant protein with GST tag.

    Sequence

    RTSSSEAHIPDQETTSLTSGTGTPGAEAEQQDTASVEQSSQKECGQPAGQVAVLPEVQVTQNPANEQESAEPKTVEEEESNFSSPLMLWLQQEQKRKESITEKKPKKGLV

    Host

    Mouse

    Reactivity

    Human

    Quality Control Testing

    Antibody Reactive Against Recombinant Protein.

    Western Blot detection against Immunogen (38.21 KDa) .

    Storage Buffer

    50 % glycerol

    Storage Instruction

    Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.

  • Applications

    Western Blot (Recombinant protein)

    ELISA

  • Gene Info — MLL

    Entrez GeneID

    4297

    GeneBank Accession#

    NM_005933

    Protein Accession#

    NP_005924

    Gene Name

    MLL

    Gene Alias

    ALL-1, CXXC7, FLJ11783, HRX, HTRX1, KMT2A, MLL/GAS7, MLL1A, TET1-MLL, TRX1

    Gene Description

    myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila)

    Omim ID

    159555

    Gene Ontology

    Hyperlink

    Gene Summary

    The MLL gene encodes a DNA-binding protein that methylates histone H3 (see MIM 601128) lys4 (H3K4) and positively regulates expression of target genes, including multiple HOX genes (see MIM 142980). MLL is a frequent target for recurrent translocations in acute leukemias that may be characterized as acute myeloid leukemia (AML; MIM 601626), acute lymphoblastic leukemia (ALL), or mixed lineage (biphenotypic) leukemia (MLL). Leukemias with translocations involving MLL possess unique clinical and biologic characteristics and are often associated with poor prognosis. MLL rearrangements are found in more than 70% of infant leukemias, whether the immunophenotype is more consistent with ALL or AML6, but are less frequent in leukemias from older children. MLL translocations are also found in approximately 10% of AMLs in adults, as well as in therapy-related leukemias, most often characterized as AML, that develop in patients previously treated with topoisomerase II inhibitors for other malignancies. More than 50 different MLL fusion partners have been identified. Leukemogenic MLL translocations encode MLL fusion proteins that have lost H3K4 methyltransferase activity. A key feature of MLL fusion proteins is their ability to efficiently transform hematopoietic cells into leukemia stem cells (Krivtsov and Armstrong, 2007 [PubMed 17957188]).[supplied by OMIM

    Other Designations

    CDK6/MLL fusion protein|MLL-AF4 der(11) fusion protein|MLL/GAS7 fusion protein|MLL/GMPS fusion protein|trithorax-like protein|zinc finger protein HRX

  • Interactome
  • Disease
Contact Info
  • +1-909-264-1399
    +1-909-992-0619
    Toll Free : +1-877-853-6098
  • +1-909-992-3401
4 Products to Compare
Remove All